Brief: Caribou Biosciences Announces Dosing Of First Patient In The CaMMouflage Phase 1 Trial Of CB-011

Caribou Biosciences

29/03/2023 15:06

March 29 (Reuters) - Caribou Biosciences Inc  CRBU.O :
    * CARIBOU BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN
THE
CAMMOUFLAGE PHASE 1 TRIAL OF CB-011, AN ALLOGENEIC ANTI-BCMA
CAR-T CELL THERAPY FOR THE TREATMENT OF RELAPSED OR REFRACTORY
MULTIPLE MYELOMA
    * CARIBOU BIOSCIENCES INC - CB-011 IS CARIBOU'S SECOND
PROGRAM TO
ENTER CLINIC FROM ITS OFF--SHELF CAR-T CELL THERAPY PLATFORM
    * CARIBOU BIOSCIENCES INC - CARIBOU PLANS TO CONTINUE TO
ENROLL
ADDITIONAL PATIENTS AT DOSE LEVEL 1 IN CAMMOUFLAGE TRIAL

Source text for Eikon:  ID:nGNX6ZjJLS 
Further company coverage:  CRBU.O